Tags

Type your tag names separated by a space and hit enter

MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Eur J Cancer. 2015 Aug; 51(12):1603-10.EJ

Abstract

MED12 is a subunit of the multiprotein complex Mediator, an evolutionary-conserved regulator of transcription. Oncogenic mutations in exon 2 of MED12 occur in nearly 70% of uterine leiomyomas, and together with HMGA, represent the most common genetic anomalies in leiomyoma. This mutational anomaly represents a driver mutation. MED12 mutations are restricted to benign smooth muscle tumours (leiomyomas) of the uterus or of the Müllerian system, but decreased protein expression has also been observed in uterine leiomyosarcomas independently of mutational status, suggesting a possible epigenetic mechanism. The discovery of MED12 involvement in leiomyoma genesis has dramatically contributed to increasing our knowledge on leiomyomas, but many questions remain. Here we summarise the current state of knowledge and perspectives on the role of MED12 in the genesis of uterine smooth muscle tumours.

Authors+Show Affiliations

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France; Institut National de la Santé et de la Recherche Medicale (INSERM) U916, F-33000 Bordeaux, France. Electronic address: s.croce@bordeaux.unicancer.fr.Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France; Institut National de la Santé et de la Recherche Medicale (INSERM) U916, F-33000 Bordeaux, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26037152

Citation

Croce, Sabrina, and Frédéric Chibon. "MED12 and Uterine Smooth Muscle Oncogenesis: State of the Art and Perspectives." European Journal of Cancer (Oxford, England : 1990), vol. 51, no. 12, 2015, pp. 1603-10.
Croce S, Chibon F. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. Eur J Cancer. 2015;51(12):1603-10.
Croce, S., & Chibon, F. (2015). MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. European Journal of Cancer (Oxford, England : 1990), 51(12), 1603-10. https://doi.org/10.1016/j.ejca.2015.04.023
Croce S, Chibon F. MED12 and Uterine Smooth Muscle Oncogenesis: State of the Art and Perspectives. Eur J Cancer. 2015;51(12):1603-10. PubMed PMID: 26037152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. AU - Croce,Sabrina, AU - Chibon,Frédéric, Y1 - 2015/05/30/ PY - 2015/04/13/received PY - 2015/04/24/accepted PY - 2015/6/4/entrez PY - 2015/6/4/pubmed PY - 2015/9/22/medline KW - Leiomyoma KW - Leiomyosarcoma KW - MED12 KW - STUMP KW - Uterus SP - 1603 EP - 10 JF - European journal of cancer (Oxford, England : 1990) JO - Eur. J. Cancer VL - 51 IS - 12 N2 - MED12 is a subunit of the multiprotein complex Mediator, an evolutionary-conserved regulator of transcription. Oncogenic mutations in exon 2 of MED12 occur in nearly 70% of uterine leiomyomas, and together with HMGA, represent the most common genetic anomalies in leiomyoma. This mutational anomaly represents a driver mutation. MED12 mutations are restricted to benign smooth muscle tumours (leiomyomas) of the uterus or of the Müllerian system, but decreased protein expression has also been observed in uterine leiomyosarcomas independently of mutational status, suggesting a possible epigenetic mechanism. The discovery of MED12 involvement in leiomyoma genesis has dramatically contributed to increasing our knowledge on leiomyomas, but many questions remain. Here we summarise the current state of knowledge and perspectives on the role of MED12 in the genesis of uterine smooth muscle tumours. SN - 1879-0852 UR - https://www.unboundmedicine.com/medline/citation/26037152/MED12_and_uterine_smooth_muscle_oncogenesis:_State_of_the_art_and_perspectives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(15)00385-8 DB - PRIME DP - Unbound Medicine ER -